Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis

American Journal of Gastroenterology

Volumn 97, Issue 10, 2002, Pages 2577-2584

  Su, Chinyu ^a   Salzberg, Bruce A ^b   Lewis, James D ^a   Deren, Julius J ^a   Kornbluth, Asher ^c   Katzka, David A ^a   Stein, Robert B ^a   Adler, Douglas R ^d   Lichtenstein, Gary R ^a,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Atlanta Gastroenterology Associates   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; OUTPATIENT; PREDICTION; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; STEROID THERAPY; TOTAL COLON RESECTION; TREATMENT FAILURE; ULCERATIVE COLITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036792705     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04384-8     Document Type: Article

References (31)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
2. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
3. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
4. Masuda H, Iwai S, Tanaka T, et al. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995;46:111-23.
5. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
6. Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996;16:144-50.
7. Nielsen OH, Gionchetti P, Ainsworth M, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999;94:2923-8.
8. Saiki T, Mitsuyama K, Toyonaga A, et al. Detection of proand anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998;33:616-22.
9. Watkins PE, Warren BF, Stephens S, et al. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut 1997;40:628-33.
10. Evans RC, Clarke L, Heath P, et al. Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571. Aliment Pharmacol Ther 1997;11:1031-5.
11. Chey WY, Hussain A, Ryan C, et al. Infliximab is an effective therapeutic agent for ulcerative colitis. Am J Gastroenterol 2000;95:A2530-1.
12. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001;7(suppl)1:S30-3.
13. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflamm Bowel Dis 2001;7:83-8.
14. Chey WY, Hussain A, Ryan C, et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96:2373-81.
15. Lewis JD, Lichtenstein GR, Stein RB, et al. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001;96:3323-8.
16. Sutherland LR, Martin F. 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada. Dig Dis Sci 1987;32(suppl 12):64S-6S.
17. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92:1894-8.
18. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
19. Roberts WG, Simon TJ, Berlin RG, et al. Leukotrienes in ulcerative colitis: Results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 1997;112:725-32.
20. Ardizzone S, Molteni P, Imbesi V, et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997;25:330-3.
21. Hanauer SB, Lichtenstein GR, Columbel J-F, et al. Maintenance infliximab (Remicade) is safe, effective and steroid-sparing in Crohn's disease: Preliminary results from the ACCENT I trial. Gastroenterology 2001;120:A21.
22. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: A five-year experience. Am J Gastroenterol 1999;94:1587-92.
23. Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis: Short-term and long-term responses. Dig Dis Sci 1996;41:2471-6.
24. Marcello PW, Schoetz DJ Jr, Roberts PL, et al. Evolutionary changes in the pathologic diagnosis after the ileoanal pouch procedure. Dis Colon Rectum 1997;40:263-9.
25. van Deventer SJ. Anti-TNF antibody treatment of Crohn's disease. Ann Rheum Dis 1999;58(suppl 1):1114-20.
26. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
27. Warris A, Bjomeklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099-100.
28. Keenan GF, Schaible TF, Boscia JA. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099-100.
29. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factoralpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-72.
30. Allendoerfer R, Deepe GS Jr. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 1998;160:6072-82.
31. Aberra F, Lewis JD, Lichtenstein GR. Is preoperative azathioprine (AZA), 6-mercaptopurine (6-MP) or corticosteroids (CS) use for elective bowel surgery associated with postoperative infectious complications? Gastroenterology 2001;120: A623.